n-3脂肪酸可降低慢性肾病患者的血浆20-羟基二十碳四烯酸水平及血压。
n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease.
作者信息
Barden Anne E, Burke Valerie, Mas Emilie, Beilin Lawrence J, Puddey Ian B, Watts Gerald F, Irish Ashley B, Mori Trevor A
机构信息
aSchool of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia bDepartment of Nephrology and Transplantation, Royal Perth Hospital, Perth, Western Australia, Australia.
出版信息
J Hypertens. 2015 Sep;33(9):1947-53. doi: 10.1097/HJH.0000000000000621.
BACKGROUND
Metabolism of arachidonic acid by cytochrome P450 ω-hydroxylase leads to the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) that regulates vascular function, sodium homeostasis and blood pressure (BP). Supplementation with n-3 fatty acids is known to alter arachidonic acid metabolism and reduce the formation of the lipid peroxidation products F2-isoprostanes, but the effect of n-3 fatty acids on 20-HETE has not been studied.
METHOD
We previously reported a significant effect of n-3 fatty acids but not coenzyme Q10 (CoQ) to reduce BP in a double-blind, placebo-controlled intervention, wherein patients with chronic kidney disease (CKD) were randomized to n-3 fatty acids (4 g), CoQ (200 mg), both supplements or control (4 g olive oil), daily for 8 weeks. This study examined the effect of n-3 fatty acids on plasma and urinary 20-HETE in the same study, as well as plasma and urinary F2-isoprostanes, and relate these to changes in BP.
RESULTS
Seventy-four patients completed the 8-week intervention. n-3 fatty acids but not CoQ significantly reduced plasma 20-HETE (P = 0.001) and F2-isoprostanes (P < 0.001). In regression models adjusted for BP at baseline, postintervention plasma 20-HETE was a significant predictor of the fall in SBP (P < 0.0001) and DBP (P < 0.0001) after n-3 fatty acids.
CONCLUSION
This is the first report that n-3 fatty acid supplementation reduces plasma 20-HETE in humans and that this associates with reduced BP. These results provide a plausible mechanism for the reduction in BP observed in patients with CKD following n-3 fatty acid supplementation.
背景
细胞色素P450 ω-羟化酶对花生四烯酸的代谢导致20-羟基二十碳四烯酸(20-HETE)的形成,其可调节血管功能、钠稳态和血压(BP)。已知补充n-3脂肪酸可改变花生四烯酸代谢并减少脂质过氧化产物F2-异前列腺素的形成,但n-3脂肪酸对20-HETE的影响尚未得到研究。
方法
我们之前报道了在一项双盲、安慰剂对照干预中,n-3脂肪酸而非辅酶Q10(CoQ)对降低血压有显著作用,其中慢性肾脏病(CKD)患者被随机分为每日服用n-3脂肪酸(4克)、CoQ(200毫克)、两种补充剂或对照(4克橄榄油),持续8周。本研究在同一研究中检测了n-3脂肪酸对血浆和尿液中20-HETE以及血浆和尿液中F2-异前列腺素的影响,并将这些与血压变化相关联。
结果
74名患者完成了为期8周的干预。n-3脂肪酸而非CoQ显著降低了血浆20-HETE(P = 0.001)和F2-异前列腺素(P < 0.001)。在针对基线血压进行调整的回归模型中,干预后血浆20-HETE是n-3脂肪酸治疗后收缩压(SBP)下降(P < 0.ooo1)和舒张压(DBP)下降(P < 0.0001)的显著预测指标。
结论
这是首份关于补充n-3脂肪酸可降低人体血浆20-HETE且这与血压降低相关的报告。这些结果为CKD患者补充n-3脂肪酸后血压降低提供了一种合理机制。